A Study to Evaluate the Use of Placenta Protein 13 (PP13) in the First Trimester of Pregnancy as a Diagnostic Aiding Tool in the Assessment of the Risk for Developing Preeclampsia in Women With Low and Unknown Risk

Completed

Conditions studied: Preeclampsia

In brief

The purpose of this study is to evaluate whether it is possible to detect changes in the concentration of PP13 in the blood of pregnant women who may go on to develop the complication of preeclampsia later on in the pregnancy, and if these changes can be detected early enough to allow early diagnosis and treatment for prevention of these complications and reduce their damage. This study will test if the PP13 biomarker during the first trimester of pregnancy has the ability to provide assessment of risk for the development of preeclampsia that necessitates delivery before 37 weeks gestation or can predict preeclampsia before 34 weeks gestation.

Key facts

Study ID

NCT00572793

Run by

Carl Weiner, MD

People needed

431

Starts

2007-11-01

Expected to finish

2014-07-01

Last updated by the study team

2015-07-08

Who can join

Age: 16 and older, up to 45. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Healthy, pregnant females
• Singleton fetus at 7 0/7 to 13 6/7 weeks gestation

You may not qualify if…

• Multi-fetal pregnancy
• Mental retardation
• Known fetal anomaly or demise
• BMI > 35, serious medical condition

Where it is running

• University of Kansas Medical Center — Kansas City, Kansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.